STUDY OF SPECIFICITY, SENSITIVITY, EFFICIENCY & CLINICAL CORRELATION BETWEEN TIMP-1 AND MIF PROTEIN AS BIOCHEMICAL MARKERS IN COLORECTAL CANCER PATIENTS
AbstractBackground: Colorectal cancer is the fifth most common cancer and the leading cause of cancer-related deaths in India. The incidence, mortality, and prevalence rates are consistently higher. Precautionary measures in preventing colorectal cancer still remain a challenging issue. Aims and Objectives: This study was undertaken to correlate the specificity, sensitivity & efficiency of TIMP-1 and MIF protein that are non-invasive and enable us to detect CRC quite early. Analysis of CEA, Ca19-9, Fecal Hemoglobin were done as diagnostic markers & TIMP-1, MIF protein, CRP, prolactin as prognostic and molecular markers. Total 120 patients were included in the study and categorized as stage I-IV with recurrences and without recurrences which were compared with healthy controls. Results: The study observed increased CEA, CA19-9, fecal Hb in various stages of colorectal cancer as compared to control. Prolactin, CRP, TIMP-1, MIF Protein show significant (p<0.001) rise in various stages. The elevated levels are increased concomitantly from stage 0 to IV suggesting the severity and distance spread of the disease. CEA, CA19-9, and fecal Hb have high specificity & prolactin, CRP, MIF, TIMP-1 protein have high sensitivity. TIMP-1 and MIF protein showed a significant correlation with other biochemical parameters. Conclusions: Increased sensitivity and specificity in CRC suggest that biomarkers are highly suitable for early tumor detection. Monitoring of these will be of great diagnostic importance, and this will be challenging in the clinical utility of the CRC patients and increase their survival rate.
Article Information
34
3298-3303
615 KB
284
English
IJPSR
Padmini Habbu *, N. Ananthi and Abdul Kayyum Shaikh
Department of Biochemistry, Saveetha Medical College and Hospital Chennai, Tamil Nadu, India.
phabbu18@gmail.com
21 December 2021
02 February 2022
28 April 2022
10.13040/IJPSR.0975-8232.13(8).3298-03
01 August 2022